Physician profile
Robert A Boton
NPI 1134129323
$2,066.08
in general payments reported to CMS, 2019-2025
27 companies · $390 in 2025
The $390 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $180 · 2021: $278 · 2022: $138 · 2023: $390 · 2024: $432 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $261.71 | 2019-2025 | Vaxneuvance, Vaxelis, M-M-R II |
| Sanofi Pasteur INC. | $244.57 | 2021-2025 | |
| Pfizer INC. | $214.71 | 2019-2025 | |
| Cranial Technologies, INC | $190.77 | 2019-2024 | Doc Band |
| Seqirus USA INC | $190.53 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Sobi, INC | $154.52 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.25 | 2020-2021 | |
| Kaleo, INC. | $73.86 | 2019-2024 | Auvi-Q |
| Ironshore Pharmaceuticals INC. | $67.06 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $56.04 | 2025 | Neffy |
| Alk-Abello, INC | $52.80 | 2025 | Neffy |
| Verrica Pharmaceuticals INC. | $50.28 | 2024 | Ycanth |
| Adlon Therapeutics L.P. | $44.61 | 2019-2021 | |
| Abbvie INC. | $34.28 | 2025 | |
| Neurocrine Biosciences, INC. | $31.54 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $31.46 | 2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Shire North American Group INC | $29.33 | 2019 | |
| Alexion Pharmaceuticals, INC. | $28.62 | 2023 | Strensiq |
| Vertical Pharmaceuticals, LLC | $27.91 | 2019 | |
| Tolmar, INC. | $27.88 | 2025 | Fensolvi |
| Astrazeneca Pharmaceuticals Lp | $27.72 | 2023 | Flumist Quadrivalent |
| Sanofi-Aventis U.S. LLC | $22.16 | 2024 | |
| Tris Pharma INC | $20.79 | 2020 | |
| Amneal Pharmaceuticals LLC | $18.08 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $15.64 | 2020 | |
| Phadia US INC. | $11.89 | 2022 | |
| Glaxosmithkline, LLC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Boton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.